{"id":745066,"date":"2015-12-07T08:00:00","date_gmt":"2015-12-07T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/"},"modified":"2025-11-07T01:24:44","modified_gmt":"2025-11-07T06:24:44","slug":"merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/","title":{"rendered":"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea"},"content":{"rendered":"<p class=\"bwalignc\">       Samsung Bioepis\u2019 Second Immunology Biosimilar Approved, to be        Commercialized Under Partnership with Merck     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that Samsung Bioepis Co., Ltd. has received approval of<br \/>\n      RENFLEXIS\u2122 (infliximab), a biosimilar of the immunology medicine<br \/>\n      Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck<br \/>\n      will commercialize Samsung Bioepis\u2019 RENFLEXIS in Korea as part of<br \/>\n      Merck\u2019s commercialization partnership with Samsung Bioepis to offer<br \/>\n      high-quality biosimilar alternatives to existing biologic medicines.\n    <\/p>\n<p>\n      Samsung Bioepis\u2019 RENFLEXIS is indicated in Korea for the treatment of<br \/>\n      rheumatoid arthritis, ankylosing spondylitis, Crohn\u2019s disease,<br \/>\n      ulcerative colitis, psoriatic arthritis and plaque psoriasis in adult<br \/>\n      patients (age 18 years and older). Merck plans to launch RENFLEXIS in<br \/>\n      South Korea in the first half of 2016.\n    <\/p>\n<p>\n      \u201cMerck is committed to delivering on the promise of biosimilars and we<br \/>\n      look forward to bringing RENFLEXIS forward to help meet the needs of<br \/>\n      physicians, patients and healthcare systems,\u201d said Dora Bibila, general<br \/>\n      manager, Merck Biosimilars.\n    <\/p>\n<p>\n      Merck\u2019s commercial launch of RENFLEXIS in Korea will include<br \/>\n      comprehensive education and support services for healthcare<br \/>\n      professionals, patients and their caregivers, including biosimilars<br \/>\n      education, disease education, and reimbursement and access support.\n    <\/p>\n<p>\n      <b>About the Merck and Samsung Bioepis collaboration<\/b>\n    <\/p>\n<p>\n      Merck and Samsung Bioepis announced in February 2013 a development and<br \/>\n      commercialization agreement under which Merck will commercialize<br \/>\n      multiple biosimilar candidates in certain partnered territories. Under<br \/>\n      terms of the agreement, Samsung Bioepis is responsible for preclinical<br \/>\n      and clinical development, process development and manufacturing,<br \/>\n      clinical trials and regulatory registration. Under a separate<br \/>\n      development and commercialization agreement with Samsung Bioepis<br \/>\n      announced in February 2014, Merck is responsible for the development,<br \/>\n      registration, manufacturing and commercialization of MK-1293 (insulin<br \/>\n      glargine) worldwide.\n    <\/p>\n<p>\n      Merck will be responsible in its partnered territories for<br \/>\n      commercialization of the following biosimilar candidates in immunology,<br \/>\n      oncology and diabetes [Merck partnered territories]:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        SB2 Remicade (infliximab) [worldwide ex-EU\/Russia\/Turkey]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB4 Enbrel (etanercept) [worldwide ex-U.S.\/EU\/Japan]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB5 Humira (adalimumab) [worldwide ex-EU\/Russia\/Turkey]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB3 Herceptin (trastuzumab) [worldwide]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-1293 Lantus (insulin glargine) [worldwide]\n      <\/li>\n<\/ul>\n<p>\n      <b>About Samsung Bioepis Co., Ltd.<\/b>\n    <\/p>\n<p>\n      Samsung Bioepis was established in 2012 with a mission to develop<br \/>\n      affordable, high-quality biopharmaceutical products and to provide<br \/>\n      better patient access to these life-enhancing medications. The company<br \/>\n      aims to be the world\u2019s leading biopharmaceutical company through<br \/>\n      innovations in product development and quality assurance. Samsung<br \/>\n      Bioepis has commercial agreements with Biogen and Merck to commercialize<br \/>\n      and distribute biosimilar products in immunology, oncology and diabetes.<br \/>\n      Samsung Bioepis is a joint venture between Samsung Biologics and Biogen.<br \/>\n      For more information, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=www.samsungbioepis.com&amp;index=1&amp;md5=c435606b8c455e7182de6bcab135c9a4\" rel=\"nofollow\">www.samsungbioepis.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=962b8294c67462e52b2030cbe98bab03\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=1d6884256cb8dba11081bddafdc4280c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=04427513795cf8b402e3d801f5a0616a\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=6698f7d36dea868c240085021562643b\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=d763ac7ab2b9d814cd91fdae9134bc40\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51237646&amp;newsitemid=20151207005084&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=ab5dbb951ce0234d242dc126b1aefb89\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151207005084r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Robert        Consalvo, 908-236-1127<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Samsung Bioepis\u2019 Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS\u2122 (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis\u2019 RENFLEXIS in Korea as part of Merck\u2019s commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Samsung Bioepis\u2019 RENFLEXIS is indicated in Korea for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis in adult patients (age 18 years and older). Merck plans to launch RENFLEXIS in South Korea in the first half of 2016. \u201cMerck is committed to delivering on the promise of biosimilars and we look forward to bringing<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745066","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Samsung Bioepis\u2019 Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS\u2122 (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis\u2019 RENFLEXIS in Korea as part of Merck\u2019s commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Samsung Bioepis\u2019 RENFLEXIS is indicated in Korea for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis in adult patients (age 18 years and older). Merck plans to launch RENFLEXIS in South Korea in the first half of 2016. \u201cMerck is committed to delivering on the promise of biosimilars and we look forward to bringing\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\\\/\",\"name\":\"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-12-07T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea - Merck.com","og_description":"Samsung Bioepis\u2019 Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS\u2122 (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis\u2019 RENFLEXIS in Korea as part of Merck\u2019s commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Samsung Bioepis\u2019 RENFLEXIS is indicated in Korea for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis in adult patients (age 18 years and older). Merck plans to launch RENFLEXIS in South Korea in the first half of 2016. \u201cMerck is committed to delivering on the promise of biosimilars and we look forward to bringing","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:44+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/","name":"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-12-07T08:00:00+00:00","dateModified":"2025-11-07T06:24:44+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-receives-approval-of-renflexis-infliximab-a-biosimilar-of-remicade-in-korea\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS\u2122 (Infliximab), a Biosimilar of Remicade, in Korea"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2c82818d-7d4e-4152-8b12-1a8ba9b3efc2","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Samsung-Bioepis-Receives-Approval-of-RENFLEXIS-Infliximab-a-Biosimilar-of-Remicade-in-Korea-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745066\/revisions"}],"predecessor-version":[{"id":3674562,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745066\/revisions\/3674562"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745066"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}